儿科的脂质组氨基酸B预防:一个系统的审查
Emma V Thorley1,2, Jennifer Hatch3, Monica Li3
1Centre for Neonatal and Paediatric Infection, City St. George's, University of London, London, UK.
The Journal of antimicrobial chemotherapy
|June 10, 2025
概括
这次审查发现,对脂质体安二乙 (LAmB) 预防的儿科数据有限,突破性侵袭性真菌病 (IFD) 在7.2%的患者中. 需要进一步的研究来确定最佳的剂量和疗效.
科学领域:
- 儿科药理学 儿科药理学
- 传染病 传染病 传染病
- 系统审查是系统的审查.
背景情况:
- 脂质体安二乙 (LAmB) 经常用于高风险儿科患者的侵入性真菌病 (IFD) 预防.
- 在LAmB的剂量和频率中存在显著的变化,需要对当前证据进行审查.
研究的目的:
- 系统地评估有关儿童预防性LAmB使用的已公布数据.
- 在接受LAmB预防的儿科患者中报告突破IFD率和相关的毒性概况.
主要方法:
- 在EMBASE,Medline,Web of Science和Cochrane数据库进行系统搜索,截至2023年12月7日.
- 包括20项研究 (3项试验,12个队列,2项调查,3项PK研究) 涉及2015名患者,遵守PRISMA指南.
主要成果:
- 突破性IFD发生在7.2%的患者 (49/676).
- 常见的毒性包括低血 (23.2%) 和异常的肝功能测试 (15.0%).
- 在6.0%的患者中,由于毒性而停止治疗.
结论:
- 显著缺乏可靠的儿科数据支持预防性LAmB的广泛使用.
- 研究设计和剂量方案的异质性阻止了关于疗效或最佳剂量策略的最终结论.
- 高质量的临床试验和有针对性的药理动力学研究对于儿童的基于证据的LAmB预防至关重要.
相关概念视频
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...


